Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer

Immunobiology

Volumn 216, Issue 10, 2011, Pages 1065-1073

  Motadi, Lesetja R ^a   Bhoola, Kanti D ^b   Dlamini, Zodwa ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SOUTH AFRICA   (South Africa)

Author keywords

Lung cancer; P53 protein; Retinoblastoma binding protein 6

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN; RETINOBLASTOMA BINDING PROTEIN 6; RETINOBLASTOMA PROTEIN; RING FINGER PROTEIN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MITOSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RETINOBLASTOMA BINDING PROTEIN 6 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; TUMOR DIFFERENTIATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARRIER PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052097665     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.05.004     Document Type: Article

References (30)

1. Baker A., Payne C.M., Briehl M.M., Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 1997, 57:5162-5167.
2. Benedict W.F., Xu H.J., Hu S.X., Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J. Clin. Invest. 1990, 85:988-993.
3. Benedict W.F., Xu H.J., Takahashi R. The retinoblastoma gene: its role in human malignancies. Cancer Invest. 1990, 8:535-540.
4. Chibi M., Meyer M., Skepu A.G., Rees D.J., Moolman-Smook J.C., Pugh D.J. RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. J. Mol. Biol. 2008, 384:908-916.
5. Franklin W.A. Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest 2000, 117:80S-89S.
6. Gewirtz D.A., Randolph J.K., Chawla J., Orr M.S., Fornari F.A. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother. Pharmacol. 1998, 141:361-369.
7. Gurnani M., Lipari P., Dell J., Shi B., Nielsen L.L. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 1999, 44:143-151.
8. Homer C., Knight D.A., Hananeia L., et al. Y-box factor YB1 controls p53 apoptotic function. Oncogene 2005, 24:8314-8325.
9. Jaruga E., Salvioli S., Dobrucki J., Chrul S., Bandorowicz-Pikuła J., Sikora S., Franceschi C., Cossarizza A., Bartosz G. Apoptosis-like reversible changes in plasma membrane asymmetry and permeability, and transient modification in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett. 1998, 433:287-293.
10. Lasham A., Moloney S., Hale T., et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J. Biol. Chem. 2003, 278:35516-35523.
11. Motadi L.R., Misso N.L., Dlamini Z., Bhoola K.D. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. Int. Immunopharmacol. 2007, 7:1934-1947.
12. Motoyama S., Ladines-Llave C.A., Luis Villanueva S., Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 2004, 50:9-19.
13. Nemunaitis J., O'Brien J. Biological approaches to treatment of head and neck cancer. BioDrugs 2000, 13:359-372.
14. Oren M. Decision making by p53: life, death and cancer. Cell Death Diff. 2003, 10:431-442.
15. Pugh D.J., Ab E., Faro A., Lutya P.T., Hoffmann E., Rees D.J. DWNN, a novel ubiquitin-like domain, implicates RBBP6 in mRNA processing and ubiquitin-like pathways. BMC Struct. Biol. 2006, 6:1.
16. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998, 17:554-564.
17. Saijo M., Sakai Y., Kishino T., et al. Molecular cloning of a human protein that binds to the retinoblastoma protein and chromosomal mapping. Genomics 1995, 27:511-519.
18. Sakai Y., Saijo M., Coelho K., Kishino T., Niikawa N., Taya Y. cDNA sequence and chromosomal localization of a novel human protein, RBQ-1 (RBBP6), that binds to the retinoblastoma gene product. Genomics 1995, 30:98-101.
19. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112.
20. Simons M., Ariyoshi H., Salzman E.W., Rosenberg R.D. c-myb affects intracellular calcium handling in vascular smooth muscle cells. Am. J. Physiol. 1995, 268:C856-C868.
21. Simons A., Melamed-Bessudo C., Wolkowicz R., et al. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene 1997, 14:145-155.
22. Snell V., Clodi K., Zhao S., Goodwin R., Thomas E.K., Morris S.W., Kadin M.E., Cabanillas F., Andreeff M., Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 1997, 99(3):618-624.
23. Swisher S.G., Roth J.A., Komaki R., et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 2003, 9:93-101.
24. Terasaki H., Hayashida K., Daiba A., et al. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 2005, 3:1253-1259.
25. Watanabe K., Peraud A., Gratas C., Wakai S., Kleihues P., Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol. 1998, 95:559-564.
26. Witte M.M., Scott R.E. The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucleoprotein association and Rb1 binding shows repressed expression during terminal differentiation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1212-1217.
27. Yoshitake Y., Nakatsura T., Monji M., et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin. Cancer Res, 2004, 10:6437-6448.
28. Zhao J., Wang M., Chen J., et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 2002, 183:69-77.
29. Zhou P., Yao Y., Soh J.W., Weinstein I.B. Overexpression of p21Cip1 or p27Kip1 in the promyelocytic leukemia cell line HL60 accelerates its lineage-specific differentiation. Anticancer Res. 1999, 19:4935-4945.
30. Zitting A., Husgafvel-Pursianen K., Rantanen J. Environmental tobacco smoke-a major preventable cause of impaired health at work. Scand. J. Work Environ. Health 2002, 28:3-6.